GB201820157D0 - Method of treatment - Google Patents

Method of treatment

Info

Publication number
GB201820157D0
GB201820157D0 GBGB1820157.4A GB201820157A GB201820157D0 GB 201820157 D0 GB201820157 D0 GB 201820157D0 GB 201820157 A GB201820157 A GB 201820157A GB 201820157 D0 GB201820157 D0 GB 201820157D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1820157.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial College of Science Technology and Medicine
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd, Imperial Innovations Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB1820157.4A priority Critical patent/GB201820157D0/en
Publication of GB201820157D0 publication Critical patent/GB201820157D0/en
Priority to PCT/GB2019/053514 priority patent/WO2020120965A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
GBGB1820157.4A 2018-12-11 2018-12-11 Method of treatment Ceased GB201820157D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1820157.4A GB201820157D0 (en) 2018-12-11 2018-12-11 Method of treatment
PCT/GB2019/053514 WO2020120965A1 (en) 2018-12-11 2019-12-11 Modified cells for use in a method of treatment of disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1820157.4A GB201820157D0 (en) 2018-12-11 2018-12-11 Method of treatment

Publications (1)

Publication Number Publication Date
GB201820157D0 true GB201820157D0 (en) 2019-01-23

Family

ID=65030170

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1820157.4A Ceased GB201820157D0 (en) 2018-12-11 2018-12-11 Method of treatment

Country Status (2)

Country Link
GB (1) GB201820157D0 (en)
WO (1) WO2020120965A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103905A2 (en) * 2007-02-23 2008-08-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies that specifically bind irta and methods of use
BR112013033988B1 (en) * 2011-07-01 2021-10-19 Beckman Coulter, Inc. METHODS FOR IDENTIFICATION AND ISOLATION OF ONE OR MORE POPULATIONS OF IMMUNOSUPPRESSIVE REGULATORY T CELLS
CA2969384A1 (en) * 2014-12-17 2016-06-23 Cellectis Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201509413D0 (en) * 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
BR112020006106A2 (en) * 2017-09-28 2020-11-17 Immpact-Bio Ltd. methods to identify a target to prepare an inhibitory chimeric antigen receptor or a protective chimeric antigen receptor and to treat cancer in a patient having a tumor, and a safe effector immune cell

Also Published As

Publication number Publication date
WO2020120965A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
GB201804514D0 (en) Treatment of pyroptosis
SG11202104222TA (en) Method of treatment of biological surfaces
GB2567616B (en) Treatment method
EP3684342A4 (en) Method of treatment
ZA201908539B (en) Method of treatment of cancer
GB201706406D0 (en) Method of treatment
GB201815588D0 (en) Method of treatment
GB201819924D0 (en) Treatment method
GB201804515D0 (en) Treatment of necroptosis
EP3490547A4 (en) Method of treatment
ZA202001536B (en) Method for the treatment of wastewaters
GB201602802D0 (en) Method of treatment
GB201717945D0 (en) Method for treatment of cancer
SG11202105877YA (en) Method of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
HUE049463T2 (en) Method for the treatment of ballast
GB201820236D0 (en) Method of treatment
GB201820157D0 (en) Method of treatment
GB201806569D0 (en) Method of treatment
GB201804021D0 (en) Method of treatment
IL287250A (en) Method of treatment
IL290983A (en) Methods of treatment
GB201918853D0 (en) Methods of treatment
GB201801249D0 (en) Methods of treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)
COOA Change in applicant's name or ownership of the application

Owner name: OXFORD UNIVERSITY INNOVATION LIMITED

Free format text: FORMER OWNERS: IP2IPO INNOVATIONS LIMITED;OXFORD UNIVERSITY INNOVATION LIMITED

Owner name: IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE

Free format text: FORMER OWNERS: IP2IPO INNOVATIONS LIMITED;OXFORD UNIVERSITY INNOVATION LIMITED